Milestone financing and R&D collaboration advances gene therapy programs targeting chronic and age-related diseases in companion animals.

里程碑式融资与研发合作推动了针对伴侣动物慢性病及年龄相关疾病的基因治疗项目。

NORWALK, Conn.

康涅狄格州诺沃克

,

，

June 11, 2026

2026年6月11日

/PRNewswire/ -- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, congratulates its portfolio company Rejuvenate Bio on the successful close of a $6 million financing round and the announcement of a strategic research and development collaboration with Merck Animal Health..

/美通社/ -- 专注于改善人类健康寿命的疗法投资公司Lifespan Vision Ventures（LVV）祝贺其投资组合公司Rejuvenate Bio成功完成600万美元融资，并宣布与默克动物保健建立战略研发合作关系。

The financing round was led by VCapital, with participation from Merck Animal Health, Connecticut Innovations, and Digitalis. Proceeds will support continued advancement of Rejuvenate Bio's gene therapy platform and pipeline, including treatments designed to address chronic and age-associated diseases in companion animals..

本轮融资由VCapital领投，Merck Animal Health、Connecticut Innovations和Digitalis参投。所得资金将用于支持Rejuvenate Bio基因治疗平台及产品管线的持续进展，包括旨在解决伴侣动物慢性及年龄相关疾病的治疗方案。

Alongside the financing, Rejuvenate Bio and Merck Animal Health have entered into a strategic R&D collaboration focused on advancing a novel gene therapy program in animal health, leveraging Rejuvenate Bio's proprietary platform technologies and translational expertise.

除融资外，Rejuvenate Bio 与默克动物保健还达成了一项战略研发合作，旨在利用 Rejuvenate Bio 的专有平台技术和转化专业知识，推进动物健康领域的新型基因疗法项目。

Andrew Worden, Founding Partner at Lifespan Vision Ventures stated, 'We are proud to see Rejuvenate Bio reach this important milestone. The confidence shown by Merck Animal Health - both as an investor and a collaborator - speaks to the strength of the team and the promise of their science. Lifespan Vision Ventures is delighted to continue supporting their mission to address some of the most significant unmet needs in companion animal and human health.'.

Lifespan Vision Ventures 的创始合伙人 Andrew Worden 表示：“我们很高兴看到 Rejuvenate Bio 达到这一重要里程碑。默克动物保健公司作为投资者和合作伙伴所展现出的信心，彰显了该团队的实力及其科学技术的广阔前景。Lifespan Vision Ventures 非常高兴能继续支持他们的使命，以解决伴侣动物和人类健康领域一些最重大的未满足需求。”

Rejuvenate Bio is developing gene therapies aimed at extending healthy lifespan and treating chronic diseases across both veterinary and human health applications. The company's approach focuses on modifying biological pathways associated with aging through targeted genetic interventions.

Rejuvenate Bio 正在开发旨在延长健康寿命并治疗兽医和人类健康领域中慢性疾病的基因疗法。该公司的方法侧重于通过靶向基因干预来调节与衰老相关的生物通路。

About Lifespan Vision Ventures

关于Lifespan Vision Ventures

Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven solutions that promote healthy aging and extend human healthspan..

Lifespan Vision Ventures 是一家全球性风险投资公司，专注于投资早期生物技术企业，这些企业致力于开发突破性的技术，以预防和治疗与年龄相关的疾病。该公司与富有远见的创始人合作，推动基于科学的解决方案，以促进健康老龄化并延长人类的健康寿命。

Contact:

联系方式：

[email protected]

[email protected]

About Rejuvenate Bio

关于 Rejuvenate Bio

Rejuvenate Bio is a biotechnology company dedicated to developing novel gene therapies for chronic age-related diseases. Rejuvenate Bio has built a gene therapy pipeline with huge potential in chronic disease by utilizing clinically validated gene targets and a delivery approach that ensures well tolerated, durable expression.

Rejuvenate Bio 是一家生物技术公司，致力于开发针对慢性年龄相关疾病的新型基因疗法。Rejuvenate Bio 利用经临床验证的基因靶点和确保良好耐受性及持久表达的递送方法，构建了在慢性病治疗方面具有巨大潜力的基因疗法产品管线。

Founded on scientific research developed at the Wyss Institute at Harvard Medical School, Rejuvenate Bio has developed groundbreaking therapies to treat chronic age-related disease in both humans and animals. The company is headquartered in San Diego, CA..

Rejuvenate Bio 依托哈佛医学院 Wyss 研究所开发的科学研究，创立了突破性的疗法，用于治疗人类和动物的慢性年龄相关疾病。公司总部位于加利福尼亚州圣地亚哥。

For more information, visit

更多信息，请访问

www.rejuvenatebio.com

www.rejuvenatebio.com

.

。

SOURCE LifeSpan Vision Ventures

来源：LifeSpan Vision Ventures

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示